New Leadership Appointments at Ascend Advanced Therapies
Ascend Advanced Therapies, a partner in gene to GMP advanced therapy development, has recently announced the strategic appointments of John Chiminski as Chair of the Board and Karen Flynn as an Independent Director. As Ascend continues to progress in the advanced therapy sector, the expertise offered by these seasoned professionals promises to shape the company’s journey.
Expertise of John Chiminski
John Chiminski brings an impressive three-decade background rooted in healthcare and pharmaceutical services. He previously held the role of CEO at Catalent from 2009 to 2015, subsequently serving as Chair and CEO from 2016 until 2022. Under his stewardship, Catalent transformed into a significant player in the CDMO landscape, enhancing its capabilities and influence in the pharmaceutical and biopharmaceutical sectors. As a current board member of QuidelOrtho (QDEL) and a Senior Advisor for Abingworth, John’s extensive experience will be invaluable as Ascend charts its path forward.
John's Vision for Ascend
Expressing his enthusiasm for joining Ascend, Chiminski stated, "Ascend is at a pivotal moment in its growth, and I am excited to support the team as we build a world-class gene therapy CDMO. With the right strategy, investment, and operational excellence, Ascend is well-positioned to be a leading partner in advanced therapies." His forward-thinking vision aligns closely with Ascend’s commitment to excellence in gene therapy manufacturing.
Introduction of Karen Flynn
Bringing her own extensive experience, Karen Flynn joins the board equipped with a robust commercial and operations background. Her recent tenure as Interim President of BioModalities at Catalent showcases her deep understanding of the biotechnology landscape. Previously, she excelled as Chief Commercial Officer as well as President of Biologics at Catalent. Understanding the nuances of commercial operations, her strategic insights are poised to make a lasting impact on Ascend.
Insights from Karen on Ascend's Growth
Commenting on her new role, Flynn noted, "With the addition of ABL, Inc. and continued investment by EW Healthcare Partners, Ascend can support gene therapy, oncolytic, vaccine, immunotherapy, and government customers at all stages of development through to fill/finish. This world-class offering is designed to build long-term relationships with clients through a robust network."
Strategic Importance of Leadership
Mike Stella, CEO of Ascend, expressed confidence in the new board members, emphasizing how their combined leadership, strategic acumen, and industry knowledge will help shape the trajectories of advanced therapy manufacturing. Stella remarked, "Their counsel and extensive experience will be instrumental as we continue to manufacture advanced therapies and aggressively scale up the capabilities of the company."
About Ascend Advanced Therapies
Ascend Advanced Therapies specializes in tailored, cost-effective gene therapy development and manufacturing. In partnership with EW Healthcare Partners, the addition of ABL, Inc. has significantly expanded Ascend’s commercial manufacturing and development capabilities. The company's commitment to innovation and quality ensures its position as a leader in gene therapy, oncolytic, vaccine, and immunotherapy sectors.
Frequently Asked Questions
1. Who are the new appointees at Ascend Advanced Therapies?
John Chiminski is appointed as Chair of the Board, and Karen Flynn joins as an Independent Director.
2. What is John Chiminski's experience?
John has over 30 years in healthcare leadership, including significant roles at Catalent as CEO and Chair.
3. How does Karen Flynn contribute to Ascend?
Karen offers extensive operations experience, including her role as Interim President at Catalent.
4. What strategic objectives does Ascend pursue?
Ascend aims to lead in advanced therapies with a focus on quality, operational excellence, and client partnerships.
5. How can one learn more about Ascend Advanced Therapies?
Visit Ascend's official website or follow them on LinkedIn for more information and updates.
